Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 2 of 4 for:    Rivipansel | Sickle Cell Disease

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02433158
Recruitment Status : Terminated (The B5201003 OLE study was terminated based on the failure of the 'parent" B5201002 study to meet its efficacy endpoints. Termination was not due to safety.)
First Posted : May 4, 2015
Last Update Posted : February 10, 2021
Information provided by (Responsible Party):
GlycoMimetics Incorporated

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : November 15, 2019
Actual Study Completion Date : November 15, 2019
Certification/Extension First Submitted : December 22, 2020